Vladimir P. Torchilin

About

Vladimir P. Torchilin is a University Distinguished Professor of Pharmaceutical Sciences and the Director of the Center for Pharmaceutical Biotechnology and Nanomedicine at Northeastern University College of Engineering. His research focuses on drug delivery and targeting, pharmaceutical biotechnology, experimental cancer immunology, nanomedicine, pharmaceutical carriers, liposomes, micelles, dendrimers as pharmaceutical carriers, and co-delivery of siRNA and chemotherapeutics for multidrug resistant cancer, as well as hypoxia-mediated drug delivery. He has made significant contributions to the development of pharmaceutical nanocarriers, controlled drug and gene delivery, drug targeting, intracellular targeting, and cancer immunology, and has been involved in training young researchers in these areas.

Research topics

• Cancer research
• Internal medicine
• Medicine
• Materials science
• Biology
• Physics
• Mechanics
• Cell biology
• Nanotechnology
• Chemistry

Selected publications

• Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment

  Journal of Personalized Medicine · 2021 · 561 citations

  Senior authorCorresponding

  Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the…

  DOI

• Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)

  Cancers · 2023-04-01 · 248 citations

  reviewOpen accessSenior authorCorresponding

  Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that is difficult to treat due to its resistance to both radiation and chemotherapy. This resistance is largely due to the unique biology of GBM cells, which can evade the effects of conventional treatments through mechanisms such as increased resistance to cell death and rapid regeneration of cancerous cells. Additionally, the blood-brain barrier makes it difficult for chemotherapy drugs to reach GBM cells, leading to red…

  PublisherOA PDFDOI

• Handbook of Nonmedical Applications of Liposomes

  CRC Press eBooks · 2023 · 105 citations

  PublisherDOI

• Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis

  Journal of Personalized Medicine · 2023-02-23 · 78 citations

  reviewOpen accessSenior authorCorresponding

  The innovative development of nanomedicine has promised effective treatment options compared to the standard therapeutics for cancer therapy. However, the efficiency of EPR-targeted nanodrugs is not always pleasing as it is strongly prejudiced by the heterogeneity of the enhanced permeability and retention effect (EPR). Targeting the dynamics of the EPR effect and improvement of the therapeutic effects of nanotherapeutics by using EPR enhancers is a vital approach to developing cancer therapy. I…

  PublisherOA PDFDOI

• Recent strategies to overcome breast cancer resistance

  Critical Reviews in Oncology/Hematology · 2024-04-12 · 70 citations

  articleOpen accessSenior authorCorresponding

  Breast cancer is potentially a lethal disease and a leading cause of death in women. Chemotherapy and radiotherapy are the most frequently used treatment options. Drug resistance in advanced breast cancer limits the therapeutic output of treatment. The leading cause of resistance in breast cancer is endocrine and hormonal imbalance, particularly in triple negative and HER2 positive breast cancers. The efflux of drugs due to p-gp's activity is another leading cause of resistance. Breast cancer re…

  PublisherDOI

Recent grants

• NIH Grant R01EB001961

  NIH · $1.7M · 2009

• NIH Grant R01CA121838

  NIH · $1.4M · 2012

• Lipid-dendrimer micellar nanocarriers for siRNA/drug co-delivery in MDR cancer

  NIH · $1.7M · 2015–2022

Frequent coauthors

• Nina Filipczak

  Northeastern University

  59 shared

• Ed Luther

  Northeastern University

  36 shared

• Tatyana Levchenko

  Northeastern University

  36 shared

• Lívia P. Mendes

  34 shared

• Ban‐An Khaw

  31 shared

• Artiom Petrov

  First Pavlov State Medical University of St. Petersburg

  29 shared

• Jagat Narula

  The University of Texas Health Science Center at San Antonio

  28 shared

• Satya Siva Kishan Yalamarty

  Northeastern University

  26 shared

Education

• Ph.D., Pharmacology

  University of Illinois at Chicago

  1986

• M.S., Pharmacology

  University of Illinois at Chicago

  1983

• B.S., Pharmacology

  University of Illinois at Chicago

  1981

Awards & honors

• Lenin Prize of the USSR in Science and Technology (1982)
• Fellow, American Institute for Medical and Biological Engine…
• Member, European Academy of Sciences (2002)
• Fellow, American Association of Pharmaceutical Scientists (A…
• ATOMS Research Excellence in Mentorship Award, National Inst…

Similar researchers at Northeastern University

• Sanjeev Mukerjeeh-94
• Hongfei Linh-89
• George Hadjipanayish-64